Japan Breast Cancer Research Group
Clinical trials sponsored by Japan Breast Cancer Research Group, explained in plain language.
-
Second dose of targeted combo may stall breast cancer growth
Disease control CompletedThis study looked at whether giving pertuzumab again, along with trastuzumab and chemotherapy, helps people with advanced HER2-positive breast cancer live longer without their disease getting worse. It included 226 adults who had already been treated with pertuzumab before. The g…
Phase: PHASE3 • Sponsor: Japan Breast Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
New combo aims to keep cancer in check with fewer side effects
Disease control CompletedThis study tested whether a combination of eribulin, pertuzumab, and trastuzumab works as well as the standard taxane-based combo for advanced HER2-positive breast cancer, but with better quality of life. 446 women who had not received chemotherapy for advanced disease took part.…
Phase: PHASE3 • Sponsor: Japan Breast Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:02 UTC